1
|
Balasubramaniyan M, Santhanam M, Vinayagam V, Perumal K. Immunomodulatory effects of chitosan nanoparticles as vaccine delivery agent against lymphatic filariasis through mucosal immunization. Int J Biol Macromol 2022; 222:2392-2398. [DOI: 10.1016/j.ijbiomac.2022.10.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2022] [Revised: 08/18/2022] [Accepted: 10/04/2022] [Indexed: 11/05/2022]
|
2
|
Devoe NC, Corbett IJ, Barker L, Chang R, Gudis P, Mullen N, Perez K, Raposo H, Scholz J, May M. Differential Evolutionary Selection and Natural Evolvability Observed in ALT Proteins of Human Filarial Parasites. PLoS One 2016; 11:e0148611. [PMID: 26890364 PMCID: PMC4758719 DOI: 10.1371/journal.pone.0148611] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2015] [Accepted: 01/20/2016] [Indexed: 11/18/2022] Open
Abstract
The abundant larval transcript (ALT-2) protein is present in all members of the Filarioidea, and has been reported as a potential candidate antigen for a subunit vaccine against lymphatic filariasis. To assess the potential for vaccine escape or heterologous protection, we examined the evolutionary selection acting on ALT-2. The ratios of nonsynonymous (K(a)) to synonymous (K(s)) mutation frequencies (ω) were calculated for the alt-2 genes of the lymphatic filariasis agents Brugia malayi and Wuchereria bancrofti and the agents of river blindness and African eyeworm disease Onchocerca volvulus and Loa loa. Two distinct Bayesian models of sequence evolution showed that ALT-2 of W. bancrofti and L. loa were under significant (P<0.05; P < 0.001) diversifying selection, while ALT-2 of B. malayi and O. volvulus were under neutral to stabilizing selection. Diversifying selection as measured by ω values was notably strongest on the region of ALT-2 encoding the signal peptide of L. loa and was elevated in the variable acidic domain of L. loa and W. bancrofti. Phylogenetic analysis indicated that the ALT-2 consensus sequences formed three clades: the first consisting of B. malayi, the second consisting of W. bancrofti, and the third containing both O. volvulus and L. loa. ALT-2 selection was therefore not predictable by phylogeny or pathology, as the two species parasitizing the eye were selected differently, as were the two species parasitizing the lymphatic system. The most immunogenic regions of L. loa and W. bancrofti ALT-2 sequence as modeled by antigenicity prediction analysis did not correspond with elevated levels of diversifying selection, and were not selected differently than predicted antigenic epitopes in B. malayi and O. volvulus. Measurements of ALT-2 evolvability made by χ2 analysis between alleles that were stable (O. volvulus and B. malayi) and those that were under diversifying selection (W. bancrofti and L. loa) indicated significant (P<0.01) deviations from a normal distribution for both W. bancrofti and L. loa. The relationship between evolvability and selection in L. loa followed a second order polynomial distribution (R2 = 0.89), indicating that the two factors relate to one another in accordance with an additional unknown factor. Taken together, these findings indicate discrete evolutionary drivers acting on ALT-2 of the four organisms examined, and the described variation has implications for design of novel vaccines and diagnostic reagents. Additionally, this represents the first mathematical description of evolvability in a naturally occurring setting.
Collapse
Affiliation(s)
- Neil C. Devoe
- University of New England College of Osteopathic Medicine, Biddeford, Maine, 04005, United States of America
| | - Ian J. Corbett
- University of New England College of Osteopathic Medicine, Biddeford, Maine, 04005, United States of America
| | - Linsey Barker
- University of New England College of Osteopathic Medicine, Biddeford, Maine, 04005, United States of America
| | - Robert Chang
- University of New England College of Osteopathic Medicine, Biddeford, Maine, 04005, United States of America
| | - Polyxeni Gudis
- University of New England College of Osteopathic Medicine, Biddeford, Maine, 04005, United States of America
| | - Nathan Mullen
- University of New England College of Osteopathic Medicine, Biddeford, Maine, 04005, United States of America
| | - Kailey Perez
- University of New England College of Osteopathic Medicine, Biddeford, Maine, 04005, United States of America
| | - Hugo Raposo
- University of New England College of Osteopathic Medicine, Biddeford, Maine, 04005, United States of America
| | - John Scholz
- University of New England College of Osteopathic Medicine, Biddeford, Maine, 04005, United States of America
| | - Meghan May
- University of New England College of Osteopathic Medicine, Biddeford, Maine, 04005, United States of America
| |
Collapse
|
3
|
Anugraha G, Madhumathi J, Prince PR, Prita PJJ, Khatri VK, Amdare NP, Reddy MVR, Kaliraj P. Chimeric Epitope Vaccine from Multistage Antigens for Lymphatic Filariasis. Scand J Immunol 2015; 82:380-9. [PMID: 26179420 DOI: 10.1111/sji.12340] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2015] [Accepted: 06/26/2015] [Indexed: 11/29/2022]
Abstract
Lymphatic filariasis, a mosquito-borne parasitic disease, affects more than 120 million people worldwide. Vaccination for filariasis by targeting different stages of the parasite will be a boon to the existing MDA efforts of WHO which required repeated administration of the drug to reduce the infection level and sustained transmission. Onset of a filaria-specific immune response achieved through antigen vaccines can act synergistically with these drugs to enhance the parasite killing. Multi-epitope vaccine approach has been proved to be successful against several parasitic diseases as it overcomes the limitations associated with the whole antigen vaccines. Earlier results from our group suggested the protective efficacy of multi-epitope vaccine comprising two immunodominant epitopes from Brugia malayi antioxidant thioredoxin (TRX), several epitopes from transglutaminase (TGA) and abundant larval transcript-2 (ALT-2). In this study, the prophylactic efficacy of the filarial epitope protein (FEP), a chimera of selective epitopes identified from our earlier study, was tested in a murine model (jird) of filariasis with L3 larvae. FEP conferred a significantly (P < 0.0001) high protection (69.5%) over the control in jirds. We also observed that the multi-epitope recombinant construct (FEP) induces multiple types of protective immune responses, thus ensuring the successful elimination of the parasite; this poses FEP as a potential vaccine candidate.
Collapse
Affiliation(s)
- G Anugraha
- Centre for Biotechnology, Anna University, Chennai, India
| | - J Madhumathi
- Centre for Biotechnology, Anna University, Chennai, India
| | - P R Prince
- Centre for Biotechnology, Anna University, Chennai, India
| | - P J Jeya Prita
- Centre for Biotechnology, Anna University, Chennai, India
| | - V K Khatri
- Department of Biochemistry, Mahatma Gandhi Institute of Medical Sciences, Sevagram, India
| | - N P Amdare
- Department of Biochemistry, Mahatma Gandhi Institute of Medical Sciences, Sevagram, India
| | - M V R Reddy
- Department of Biochemistry, Mahatma Gandhi Institute of Medical Sciences, Sevagram, India
| | - P Kaliraj
- Centre for Biotechnology, Anna University, Chennai, India
| |
Collapse
|
4
|
Parasurama Jawaharlal JP, Rajaiah Prabhu P, Gandhirajan A, Krishnan N, Perumal K. Immunoadjuvant effect of diethylcarbamazine in experimental filariasis. Int Immunopharmacol 2015; 24:458-462. [PMID: 25576657 DOI: 10.1016/j.intimp.2014.12.034] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2014] [Revised: 12/22/2014] [Accepted: 12/24/2014] [Indexed: 11/30/2022]
Abstract
Lymphatic filariasis caused by tissue dwelling nematodes is endemic in 73 countries and drugs have been administered to control or stop the infection. Resurgence of the infection after mass drug administration necessitates the study of several parasite antigens or adjuvants for vaccine developments. In this study, diethylcarbamazine (DEC) was evaluated for its efficacy as adjuvant against the filarial parasite; Brugia malayi microfilariae (mf) by combining with the Escherichia coli expressed recombinant BmShp-1 protein. Shp-1 is one of the sheath proteins expressed by adult female and microfilarial stage of the filarial parasite. Hence, immunoprophylactic efficacy of Shp-1 using DEC and alum adjuvants was compared in BALB/c mice model by an in situ micropore chamber method. Shp-1 antibody titre was high when the mice were immunized with Shp-1 along with DEC and they exhibited balanced Th1/Th2 profile. DEC also induced significantly high T-cell proliferation (P<0.001) when stimulated with Shp-1 compared to alum. Significantly high percentage protection against B. malayi microfilariae was observed in Shp-1+DEC immunized mice groups (P<0.05) and hence it is concluded that the need of repeated drug administration can be controlled when there is a possibility of developing protective immunity in the host against mf by vaccination.
Collapse
Affiliation(s)
| | | | | | - Nithya Krishnan
- Centre for Biotechnology, Anna University, Chennai, Tamil Nadu 600 025, India.
| | - Kaliraj Perumal
- Centre for Biotechnology, Anna University, Chennai, Tamil Nadu 600 025, India.
| |
Collapse
|
5
|
Anugraha G, Madhumathi J, Jeya Prita PJ, Kaliraj P. Biodegradable poly-l-lactide based microparticles as controlled release delivery system for filarial vaccine candidate antigens. Eur J Pharmacol 2015; 747:174-80. [DOI: 10.1016/j.ejphar.2014.12.004] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2014] [Revised: 12/02/2014] [Accepted: 12/05/2014] [Indexed: 01/25/2023]
|
6
|
Aparnaa R, Mahalakshmi N, Harini A, Jeyaprita PJ, Anugraha G, Amdare NP, Khatri VK, Reddy MVR, Kaliraj P. Wuchereria bancrofti 20/22 a homologue of abundant larval transcript L3 stage filarial antigen: molecular and immunological characterization. Parasite Immunol 2014; 36:475-84. [PMID: 24888320 DOI: 10.1111/pim.12120] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2014] [Accepted: 05/30/2014] [Indexed: 11/28/2022]
Abstract
The chromadorea abundant larval transcript (ALT) family of proteins contains ALT one of the most studied putative vaccine candidate in experimental filariasis. This study reports the characterization of Wuchereria bancrofti 20/22 (Wb20/22) as a member of chromadorea, the ALT family of proteins from the L3 stage of W. bancrofti. The high reactivity with serum from the endemic normal (EN) population suggests that Wb20/22 could be a target of elicit protective immunity. The glutamic acid-rich region of Wb20/22 was predicted to harbour the longest linear B-cell epitope by insilico prediction tools. The significance of this region was revealed by studying the mutant form of Wb20/22, without acidic domain (WOAD) which was cloned, and the immune response was compared with Wb20/22. The signal sequence of Wb20/22 was also an immunodominant region, and mutant construct without signal sequence (WOSS) was cloned and characterized. The peak antibody titre elicited by WOAD was higher than Wb20/22 or WOSS, which pointed to the immunomodulatory role of glutamic acid-rich region. Wb20/22 elicited very high levels of IL-10 and diminished levels of IL-4 and IL-5 which could be the reason for low antibody titre. The prophylactic efficacy of WOAD conferred protection (62·26%) which was higher than Wb20/22 (49·82%) and WOSS (54·78%).
Collapse
Affiliation(s)
- Ramanathan Aparnaa
- Centre for Biotechnology, Anna University, Guindy, Chennai, 600025, Tamilnadu, India
| | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Sharmila S, Christiana I, Kiran P, Reddy MVR, Sankaran K, Kaliraj P. Bacterial lipid modification enhances immunoprophylaxis of filarial abundant larval transcript-2 protein in Mastomys model. Parasite Immunol 2014; 35:201-13. [PMID: 23495791 DOI: 10.1111/pim.12034] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2012] [Accepted: 02/11/2013] [Indexed: 11/29/2022]
Abstract
As in many other parasitic diseases, efficacious vaccine for lymphatic filariasis has been elusive for want of new approaches leaving billions of people either debilitated or at risk. With multiple B- and T-cell epitopes, the abundant larval transcript-2 (ALT-2) of the filarial worm, Brugia malayi, has been shown to be a promising immunoprophylactic target. To enhance its efficacy, it was lipid modified using our recently developed protein engineering tool, which then offered 30% more immunoprotection (49 vs. 79%) in Mastomys coucha model. Sustained high levels of IFN-γ (about 100 times) and high antibody titres (10-fold) elicited by lipid-modified ALT-2, as compared to the native form, indicated the maintenance of Th1/Th2 balance that is impaired in filariasis. Thus, this study provides the basis for developing efficacious vaccines for filariasis and other parasitic diseases by exploiting bacterial lipid modification.
Collapse
Affiliation(s)
- S Sharmila
- Centre for Biotechnology, Anna University, Chennai, Tamilnadu, India
| | | | | | | | | | | |
Collapse
|
8
|
Dakshinamoorthy G, Kalyanasundaram R. Evaluating the efficacy of rBmHATαc as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation. Vaccine 2013; 32:19-25. [PMID: 24211167 DOI: 10.1016/j.vaccine.2013.10.083] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2013] [Revised: 10/19/2013] [Accepted: 10/24/2013] [Indexed: 01/04/2023]
Abstract
Developing an effective vaccine against lymphatic filariasis will complement the WHO's effort to eradicate the infection from endemic areas. Currently 83 different countries are endemic for this infection and over 1 billion people are at risk. An effective vaccine coupled with mass drug administration will reduce the morbidity and social stigma associated with this gruesome disease. Several potential vaccine candidates that can confer partial protection in experimental animals have been reported from different laboratories. However, no licensed vaccines are currently available for this disease. Among the several vaccine antigens identified from our laboratory, three most promising antigens; rBmHSPαc (α crystalline domain and c-terminal extension of Heat Shock Protein 12.6), rBmALT-2 (Abundant larval transcript) and rBmTSP LEL (Tetraspanin large extracellular loop) was further developed as a recombinant fusion protein vaccine (rBmHATαc). In a mouse model this fusion protein vaccine gave close to 68% protection following a challenge infection. To improve the vaccine efficiency of rBmHATαc, in this study we evaluated various preparations of alum (AL007, AL019, Alhydrogel and Imject® Alum) as adjuvants. Our results show that mice immunized with rBmHATαc formulated in AL007 (alum from IDRI) and/or AL019 (alum plus TLR-4 agonist from IDRI) gave the highest IgG antibody titer compared to other groups. Subsequent in vivo challenge experiments confirmed that >95% protection can be achieved when AL007 or AL019 was used as the adjuvant. However, when Imject® Alum or alhydrogel was used as the adjuvant only 76% and 72% protection respectively could be achieved. These results show that AL007 or AL019 (IDRI) is an excellent choice of adjuvant for the rBmHATαc vaccine against B. malayi L3 in mice.
Collapse
Affiliation(s)
| | - Ramaswamy Kalyanasundaram
- Department of Biomedical Sciences, University of Illinois College of Medicine, Rockford, IL 61107, USA.
| |
Collapse
|
9
|
Joseph SK, Ramaswamy K. Single multivalent vaccination boosted by trickle larval infection confers protection against experimental lymphatic filariasis. Vaccine 2013; 31:3320-6. [PMID: 23735679 PMCID: PMC3713514 DOI: 10.1016/j.vaccine.2013.05.077] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2013] [Revised: 05/14/2013] [Accepted: 05/20/2013] [Indexed: 11/15/2022]
Abstract
The multivalent vaccine BmHAT, consisting of the Brugia malayi infective larval (L3) antigens heat shock protein12.6 (HSP12.6), abundant larval transcript-2 (ALT-2) and tetraspanin large extra cellular loop (TSP-LEL), was shown to be protective in rodent models from our laboratory. We hypothesize that since these antigens were identified using protective antibodies from immune endemic normal individuals, the multivalent vaccine can be augmented by natural L3 infections providing protection to the vaccinated host. This hypothesis was tested using single dose of DNA and protein or protein alone of the BmHAT vaccination in gerbils followed by live trickle L3 infection as booster dose. Vaccine-induced protection in gerbils was determined by worm establishment, micropore chamber assay and by antibody dependant cell cytotoxicity (ADCC) assay. Results were compared with the traditional prime-boost vaccination regimen. Gerbils vaccinated with BmHAT and boosted with L3 trickle infection were protected 51% (BmHAT DNA-protein) and 48% (BmHAT protein) respectively. BmHAT vaccination plus L3 trickle booster generated significant titer of antigen-specific IgG antibodies comparable to the traditional prime boost vaccination approach. BmHAT vaccination plus L3 trickle booster also generated antigen-specific cells in the spleen of vaccinated animals and these cells secreted predominantly IFN-γ and IL-4 in response to the vaccine antigens. These studies thus show that single dose of BmHAT multivalent vaccination followed by L3 trickle booster infection can confer significant protection against lymphatic filariasis.
Collapse
MESH Headings
- Animals
- Antibodies, Helminth/blood
- Antibody Formation
- Antibody Specificity
- Antibody-Dependent Cell Cytotoxicity
- Antigens, Helminth/administration & dosage
- Antigens, Helminth/genetics
- Antigens, Helminth/immunology
- Brugia malayi/immunology
- Elephantiasis, Filarial/immunology
- Elephantiasis, Filarial/prevention & control
- Gerbillinae
- Immunization
- Immunization, Secondary
- Immunoglobulin G/blood
- Interferon-gamma/immunology
- Interleukin-4/immunology
- Larva/immunology
- Mice, Inbred BALB C
- Recombinant Proteins/genetics
- Recombinant Proteins/immunology
- Spleen/cytology
- Spleen/immunology
- Vaccination/methods
- Vaccines/administration & dosage
- Vaccines/immunology
- Vaccines, DNA/administration & dosage
- Vaccines, DNA/immunology
Collapse
Affiliation(s)
- SK Joseph
- Department of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, USA
- NIH/NIAID/LMIV Twinbrook I, 5640 Fishers Lane, Rockville MD-20852
| | - K Ramaswamy
- Department of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, USA
| |
Collapse
|
10
|
Shrivastava N, Singh PK, Nag JK, Kushwaha S, Misra-Bhattacharya S. Immunization with a multisubunit vaccine considerably reduces establishment of infective larvae in a rodent model of Brugia malayi. Comp Immunol Microbiol Infect Dis 2013; 36:507-19. [PMID: 23829972 DOI: 10.1016/j.cimid.2013.05.003] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2012] [Revised: 02/20/2013] [Accepted: 05/03/2013] [Indexed: 11/28/2022]
Abstract
Although recombinant vaccines have several advantages over conventional vaccines, protection induced by single antigen vaccines is often inadequate for a multicellular helminth parasite. Therefore, immunoprophylactic efficacy of cocktail antigen vaccines comprised of several combinations of three Brugia malayi recombinant proteins BmAF-Myo, Bm-iPGM and Bm-TPP were evaluated. Myosin+TPP and iPGM+TPP provided the best protection upon B. malayi infective larval challenge with ∼70% reduction in adult worm establishment over non-vaccinated animals that was significantly higher than the protection achieved by any single antigen vaccine. Myosin+iPGM, in contrast did not provide any enhance protection over the single recombinant protein vaccines. Specific IgG, IgM level, IgG antibody subclasses levels (IgG1, IgG2a, IgG2b, IgG3), lymphocyte proliferation, reactive oxygen species level and cytokines level were also determined to elucidate the characteristics of the protective immune responses. Thus the study undertaken provided more insight into the cocktail vaccination approach to combat LF.
Collapse
Affiliation(s)
- Nidhi Shrivastava
- Divisions of Parasitology, Central Drug Research Institute CSIR, Jankipuram Extension BS10/1, Sector 10, Sitapur Road, Lucknow 226021, UP, India
| | | | | | | | | |
Collapse
|
11
|
Morris CP, Evans H, Larsen SE, Mitre E. A comprehensive, model-based review of vaccine and repeat infection trials for filariasis. Clin Microbiol Rev 2013; 26:381-421. [PMID: 23824365 PMCID: PMC3719488 DOI: 10.1128/cmr.00002-13] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
SUMMARY Filarial worms cause highly morbid diseases such as elephantiasis and river blindness. Since the 1940s, researchers have conducted vaccine trials in 27 different animal models of filariasis. Although no vaccine trial in a permissive model of filariasis has provided sterilizing immunity, great strides have been made toward developing vaccines that could block transmission, decrease pathological sequelae, or decrease susceptibility to infection. In this review, we have organized, to the best of our ability, all published filaria vaccine trials and reviewed them in the context of the animal models used. Additionally, we provide information on the life cycle, disease phenotype, concomitant immunity, and natural immunity during primary and secondary infections for 24 different filaria models.
Collapse
Affiliation(s)
- C. Paul Morris
- Department of Microbiology and Immunology, F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
- National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
| | - Holly Evans
- Department of Microbiology and Immunology, F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
| | - Sasha E. Larsen
- Department of Microbiology and Immunology, F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
| | - Edward Mitre
- Department of Microbiology and Immunology, F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
| |
Collapse
|
12
|
Dakshinamoorthy G, Samykutty AK, Munirathinam G, Reddy MV, Kalyanasundaram R. Multivalent fusion protein vaccine for lymphatic filariasis. Vaccine 2012; 31:1616-22. [PMID: 23036503 DOI: 10.1016/j.vaccine.2012.09.055] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2012] [Revised: 09/17/2012] [Accepted: 09/22/2012] [Indexed: 11/27/2022]
Abstract
Lymphatic filariasis affects approximately 3% of the whole world population. Mass drug administration is currently the major control strategy to eradicate this infection from endemic regions by year 2020. Combination drug treatments are highly efficient in controlling the infection. However, there are no effective vaccines available for human or animal lymphatic filariasis despite the identification of several subunit vaccines. Lymphatic filariasis parasites are multicellular organisms and potentially use multiple mechanisms to survive in the host. Therefore, there is a need to combine two or more vaccine candidate antigens to achieve the desired effect. In this study we combined three well characterized vaccine antigens of Brugia malayi, heat shock protein 12.6 (HSP12.6), Abundant Larval transcript-2 (ALT-2) and tetraspanin large extra cellular loop (TSP-LEL) as a multivalent fusion vaccine. Putative immune individuals carry circulating antibodies against all three antigens. Depletion of these antigen specific antibodies from the sera samples removed the ability of the sera to participate in the killing of B. malayi L3 in an antibody dependent cellular cytotoxicity (ADCC) mechanism. Vaccination trials in mice with a bivalent [HSP12.6+ALT-2 (HA), HSP12.6+TSP-LEL (HT) or TSP-LEL+ALT-2 (TA)] or trivalent [HSP12.6+ALT-2+TSP-LEL (HAT)] vaccines using DNA, protein or heterologous prime boost regimen showed that trivalent HAT vaccine either as protein alone or as heterologous prime boost vaccine could confer significant protection (95%) against B. malayi L3 challenge. Immune correlates of protection suggest a Th1/Th2 bias. These finding suggests that the trivalent HAT fusion protein is a promising prophylactic vaccine against lymphatic filariasis infection in human.
Collapse
|